Default: Seminars in Oncology

ISSN: 0093-7754

Journal Home

Journal Guideline

Seminars in Oncology Q1 Unclaimed

W.B. Saunders Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Oncology is a journal indexed in SJR in Hematology and Oncology with an H index of 130. It has an SJR impact factor of 1,773 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -


- €

Gold OA


Green OA

- €

Non OA


Seminars in Oncology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Best articles

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

View more

Acquired immunodeficiency syndrome[mdash ]Associated cancers in Sub-Saharan Africa

View more

Adjuvant bisphosphonate therapy: The future

View more

Advances in the treatment of non[ndash ]small cell lung cancer: Molecular markers take the stage

View more

Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer

View more

Analysis of skeletal-related events in breast cancer and response to therapy

View more

Angiogenesis in multiple myeloma

View more

Angiogenesis-dependent diseases

View more

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

View more

Approaches to preclinical screening of antiangiogenic agents

View more

Assessing Decisional Capacity in the Elderly

View more

Bisphosphonates in oncology: Breast cancer and beyond

View more

Bisphosphonates in the prevention of bone metastases: Current evidence

View more

Bladder cancer in Africa: Update

View more

Bone marrow angiogenesis in patients with active multiple myeloma

View more

Bone metastases: Approaches to management

View more

Cancer immunotherapy with natural killer cells

View more

Cancer in older persons: an international issue in an aging world

View more

Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction

View more

Cancer: A reality in the emerging world

View more

Cardiac toxicity of trastuzumab (herceptin): Implications for the design of adjuvant trials

View more

Cervical cancer in Latin America

View more

Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non[ndash ]small cell lung cancer

View more

Chemotherapy for the treatment of oligodendroglial tumors

View more


No comments ... Be the first to comment!